If you made any changes in Pure these will be visible here soon.

Publications 2010 2018

Filter
Article
2018

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

EURO-SKI Investigators, Jun 2018, In : Lancet Oncology. 19, 6, p. 747-757 11 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Bruck, O., Blom, S., Dufva, O., Turkki, R., Chheda, H., Ribeiro, A., Kovanen, P., Aittokallio, T., Koskenvesa, P., Kallioniemi, O., Porkka, K., Pellinen, T. & Mustjoki, S., Jul 2018, In : Leukemia. 32, 7, p. 1643-1656 14 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File
2017

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Giles, F. J., Rea, D., Rosti, G., Cross, N. C. P., Luis Steegmann, J., Griskevicius, L., le Coutre, P., Coriu, D., Petrov, L., Ossenkoppele, G. J., Mahon, F-X., Saussele, S., Hellmann, A., Koskenvesa, P., Bruemmendorf, T. H., Gastl, G., Castagnetti, F., Vincenzi, B., Haenig, J. & Hochhaus, A., Aug 2017, In : Journal of Cancer Research and Clinical Oncology. 143, 8, p. 1585-1596 12 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Ilander, M., Olsson-Stromberg, U., Schlums, H., Guilhot, J., Bruck, O., Lahteenmaki, H., Kasanen, T., Koskenvesa, P., Soderlund, S., Hoglund, M., Markevarn, B., Sjalander, A., Lotfi, K., Dreimane, A., Lubking, A., Holm, E., Bjoreman, M., Lehmann, S., Stenke, L., Ohm, L. & 11 othersGedde-Dahl, T., Majeed, W., Ehrencrona, H., Koskela, S., Saussele, S., Mahon, F-X., Porkka, K., Hjorth-Hansen, H., Bryceson, Y. T., Richter, J. & Mustjoki, S., May 2017, In : Leukemia. 31, 5, p. 1108-1116 9 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Hoffmann, V. S., Baccarani, M., Hasford, J., Castagnetti, F., Di Raimondo, F., Casado, L. F., Turkina, A., Zackova, D., Ossenkoppele, G., Zaritskey, A., Hoglund, M., Simonsson, B., Indrak, K., Sninska, Z., Sacha, T., Clark, R., Bogdanovic, A., Hellmann, A., Griskevicius, L., Schubert-Fritschle, G. & 13 othersSertic, D., Guilhot, J., Lejniece, S., Zupan, I., Burgstaller, S., Koskenvesa, P. M., Everaus, H., Costeas, P., Lindoerfer, D., Rosti, G., Saussele, S., Hochhaus, A. & Hehlmann, R., Mar 2017, In : Leukemia. 31, 3, p. 593-601 9 p.

Research output: Contribution to journalArticleScientificpeer-review

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Koskela, H. L. M., El Missiry, M., Ruusila, A., Koskenvesa, P., Bruemmendorf, T. H., Gjertsen, B. T., Janssen, J., Lotfi, K., Markevarn, B., Olsson-Stromberg, U., Stenke, L., Stentoft, J., Richter, J., Hjorth-Hansen, H., Kreutzman, A. & Mustjoki, S., Aug 2017, In : Journal of Cancer Research and Clinical Oncology. 143, 8, p. 1543-1554 12 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Hjorth-Hansen, H., Stentoft, J., Richter, J., Koskenvesa, P., Hoeglund, M., Dreimane, A., Porkka, K., Gedde-Dahl, T., Gjertsen, B. T., Gruber, F. X., Stenke, L., Eriksson, K. M., Markevarn, B., Lubking, A., Vestergaard, H., Udby, L., Bjerrum, O. W., Persson, I., Mustjoki, S., Olsson-Stromberg, U. & 1 othersNCMLSG, Sep 2016, In : Leukemia. 30, 9, p. 1853-1860 8 p.

Research output: Contribution to journalArticleScientificpeer-review

2015

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, H., Stenke, L., Soderlund, S., Dreimane, A., Ehrencrona, H., Gedde-Dahl, T., Gjertsen, B. T., Hoglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevarn, B., Ohm, L., Olsson-Stromberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., Richter, J. & 1 othersNCMLSG, Mar 2015, In : European Journal of Haematology. 94, 3, p. 243-250 8 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Kamalan kallista on vain huono hoito

Koskenvesa, P., 2015, In : Sic! Lääketietoa Fimeasta. 5, 3, p. 24-26 3 p.

Research output: Contribution to journalArticleProfessional

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmaki, H., Koskenvesa, P., Kallioniemi, O., Wennerberg, K., Heckman, C. A., Mustjoki, S. & Porkka, K., May 2015, In : Blood cancer journal. 5, 6 p., 309.

Research output: Contribution to journalArticleScientificpeer-review

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., Costeas, P., Mayer, J., Indrak, K., Everaus, H., Koskenvesa, P., Guilhot, J., Schubert-Fritschle, G., Castagnetti, F., Di Raimondo, F., Lejniece, S., Griskevicius, L., Thielen, N., Sacha, T., Hellmann, A. & 11 othersTurkina, A. G., Zaritskey, A., Bogdanovic, A., Sninska, Z., Zupan, I., Steegmann, J-L., Simonsson, B., Clark, R. E., Covelli, A., Guidi, G. & Hehlmann, R., Jun 2015, In : Leukemia. 29, 6, p. 1336-1343 8 p.

Research output: Contribution to journalArticleScientificpeer-review

2014

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians

Kekale, M., Talvensaari, K., Koskenvesa, P., Porkka, K. & Airaksinen, M., 2014, In : Patient preference and adherence. 8, p. 1619-1627 9 p.

Research output: Contribution to journalArticleScientificpeer-review

Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Koskenvesa, P., Kreutzman, A., Rohon, P., Pihlman, M., Vakkila, E., Rasanen, A., Vapaatalo, M., Remes, K., Lundan, T., Hjorth-Hansen, H., Vakkila, J., Simonsson, B., Mustjoki, S. & Porkka, K., May 2014, In : European Journal of Haematology. 92, 5, p. 413-420 8 p.

Research output: Contribution to journalArticleScientificpeer-review

2013

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S., Richter, J., Barbany, G., Ehrencrona, H., Fioretos, T., Gedde-Dahl, T., Gjertsen, B. T., Hovland, R., Hernesniemi, S., Josefsen, D., Koskenvesa, P., Dybedal, I., Markevarn, B., Olofsson, T., Olsson-Stromberg, U., Rapakko, K., Thunberg, S., Stenke, L., Simonsson, B., Porkka, K. & 2 othersHjorth-Hansen, H. & Nordic CML Study Grp, Jul 2013, In : Leukemia. 27, 7, p. 1520-1526 7 p.

Research output: Contribution to journalArticleScientificpeer-review

2011

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, B., Gedde-Dahl, T., Markevarn, B., Remes, K., Stentoft, J., Almqvist, A., Bjoreman, M., Flogegard, M., Koskenvesa, P., Lindblom, A., Malm, C., Mustjoki, S., Myhr-Eriksson, K., Ohm, L., Rasanen, A., Sinisalo, M., Sjalander, A., Stromberg, U., Bjerrum, O. W., Ehrencrona, H. & 9 othersGruber, F., Kairisto, V., Olsson, K., Sandin, F., Nagler, A., Nielsen, J. L., Hjorth-Hansen, H., Porkka, K. & Nordic CML Study Grp, 2011, In : Blood. 118, 12, p. 3228-3235 8 p.

Research output: Contribution to journalArticleScientificpeer-review